Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition

[Image: see text] Symmetric, dimeric daclatasvir (BMS-790052) is the clinical lead for a class of picomolar inhibitors of HCV replication. While specific, resistance-bearing mutations at positions 31 and 93 of domain I strongly suggest the viral NS5A as target, structural mechanism(s) for the drugs’...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Med Chem
Egile Nagusiak: Nettles, James H., Stanton, Richard A., Broyde, Joshua, Amblard, Franck, Zhang, Hongwang, Zhou, Longhu, Shi, Junxing, McBrayer, Tamara R., Whitaker, Tony, Coats, Steven J., Kohler, James J., Schinazi, Raymond F.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Chemical Society 2014
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4266333/
https://ncbi.nlm.nih.gov/pubmed/25365735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/jm501291c
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak